Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl
Preferences help
enabled [disable] Abstract
Number of results

Results found: 3

Number of results on page
first rewind previous Page / 1 next fast forward last

Search results

help Sort By:

help Limit search:
first rewind previous Page / 1 next fast forward last
|
2019
|
vol. 33
|
issue 4
27-33
EN
Introduction Several lines of evidence indicate that being overweight or obese is associated with adverse effects observed at the level of the central nervous system. It was demonstrated that overweight or obese people exhibit lower level of cognitive functions, including the ones dependent on the hippocampus (learning and memory). The majority of studies in this area are concerned with the impact of body mass on the cognitive function in elderly people. Material and methods We examined the relationship between body mass index and cognitive performance in two groups of young volunteers: overweight (18 males; aged 17 ± 0.18; BMI 26.12 ±0.91 ) and normal body weight group (27 males; aged 17.12 ± 0.14; BMI 21.55 ± 1.12). To evaluate the cognitive performance in our subjects we used face/name association test. Results The mean results in the face name/association test in overweight group were 66.05 ± 6.7%. In normal weight group were was 73.53 ± 6.19% (p<0.005). Moreover, we observed correlation between BMI and face/name association test results (p<0.005). Conclusions Our data suggest a link between body mass and the level of cognitive performance. We demonstrate that the increased body weight may have a negative effect on some cognitive function even in young people. The potential mechanism for this association remains unclear
3
52%
EN
Introduction: The presence of background HCV infection cannot be overestimated in view of the prevalence of chronic hepatitis C and the risk of adverse outcomes of this disease. Purpose of this study was to evaluate the effectiveness of the combined use of antiviral therapy (Roferon + Vero-Ribavirin) and resort factors in patients with chronic hepatitis C in the phase of replication. Material and methods: We observed 48 patients with chronic hepatitis C; the minimum level of activity of the process defined the phase of replication. Markers of HCV infection were determined by enzyme linked immunosorbent assay (ELISA) (a-HCV and HCV-Ig M). HCV RNA was determined twice by the polymerase chain reaction (PCR). Genotyping of hepatitis C virus was performed. Biochemical blood analysis and the study of HCV infection markers were carried out four times. Results of therapy were assessed immediately after the end of the resort (spa) treatment, then at 3, 6 and 12 months after starting treatment. At 12 months after starting treatment, all the observed patients had persistent clinical and biochemical remission. Elimination of the virus from the blood was noted in 56% of the control group and 74% of patients in the study group. Conclusions: For patients with moderately active HCV, the replication phase was characterized by asthenic-vegetative syndrome (100% of patients) with severe depression (22.92%), pain (77.08%) and dyspeptic syndrome (33.33%), moderate hypertransferaseemia (100%), slightly pronounced cholestasis (33% of patients), and signs of mesenchymal- inflammatory response.
first rewind previous Page / 1 next fast forward last
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.